# Cynaroside: a potential therapeutic agent targeting arachidonate 15-lipoxygenase to mitigate cerebral ischemia/reperfusion injury

**Authors:** Wenpeng Cao, Yufeng Hu, Xingyu Yu, Tingting Long, Baofei Sun, Shan Lei, Peng Xie, Wenfeng Yu

PMC · DOI: 10.3389/fneur.2024.1490640 · 2025-02-14

## TL;DR

Cynaroside may help treat brain injury after stroke by reducing inflammation and cell death through a specific enzyme.

## Contribution

This study identifies cynaroside as a novel therapeutic agent targeting Alox15 to mitigate cerebral ischemia/reperfusion injury.

## Key findings

- Cynaroside reduces infarct volume, edema, and microglial activation in tMCAO mice.
- Cynaroside inhibits Alox15 expression and pro-inflammatory cytokine production in tMCAO and OGD/R models.
- Cynaroside attenuates ferroptosis-related gene expression in cerebral ischemia/reperfusion injury.

## Abstract

Due to the anti-inflammatory and antioxidant properties of cynaroside (Cyn), it may be useful in the treatment of cerebral ischemia/reperfusion injury (I/R). This study aims to evaluate the effect of Cyn on cerebral ischemia/reperfusion injury.

Transient middle cerebral artery occlusion model (tMCAO) and oxygen and glucose deprivation/reperfusion (OGD/R) microglia models were used to evaluate the effect of Cyn. The direct interaction between Cyn and Alox15 was investigated through bioinformatics, molecular docking and biolayer interferometry.

tMCAO mice treated with Cyn show improved neurological deficits, reduced infarct volume and edema, and inhibition of microglial activation. In addition, Cyn inhibited tMCAO-induced Alox15 expression. Cyn significantly reduced the overproduction of the M1 microglia-regulated pro-inflammatory cytokines NLRP3, ASC, and cleaved caspase-1, as well as the overproduction of IL-1β and IL-18, induced by tMCAO or OGD/R. Cyn also inhibits the expression of Tfrc, COX2, and Acsl4 in tMCAO and OGD/R-treated mice and BV-2 cells.

These results suggest that Cyn may attenuate cerebral ischemia/reperfusion injury by inhibiting Alox15 to reduce inflammation and reduce ferroptosis. This study reveals the underlying molecular mechanism of Cyn in the treatment of ischemic stroke.

## Linked entities

- **Genes:** ALOX15 (arachidonate 15-lipoxygenase) [NCBI Gene 246], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], STS (steroid sulfatase) [NCBI Gene 412], Caspase1 (caspase-1) [NCBI Gene 692604], TFRC (transferrin receptor) [NCBI Gene 7037], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182]
- **Chemicals:** cynaroside (PubChem CID 5280637)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tfrc (transferrin receptor) [NCBI Gene 22042] {aka 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1}, Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 50790] {aka 9430020A05Rik, ACS4, Facl4, Lacs4}, Sts (steroid sulfatase) [NCBI Gene 20905] {aka ArsC}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Alox15 (arachidonate 15-lipoxygenase) [NCBI Gene 11687] {aka 12-LO, 12/15-LO, 15-LOX, Alox12l, L-12LO}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}
- **Diseases:** edema (MESH:D004487), ischemic stroke (MESH:D002544), inflammation (MESH:D007249), I/R (MESH:D015427), neurological deficits (MESH:D009461), infarct (MESH:D007238), middle cerebral artery occlusion (MESH:D020244), OGD (MESH:C536050)
- **Chemicals:** glucose (MESH:D005947), oxygen (MESH:D010100), Cyn (MESH:C066408)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** tMCAO — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_B0CE), BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11867947/full.md

---
Source: https://tomesphere.com/paper/PMC11867947